申请人:Sankyo Company, Limited
公开号:US05556864A1
公开(公告)日:1996-09-17
Compounds of formula (I): ##STR1## [wherein: R.sup.1 is aryl; R.sup.2 is hydrogen, alkyl, alkoxy, halogen or cyano; R.sup.3 is a group of formula --B--NR.sup.4 R.sup.5, where R.sup.4 and R.sup.5 are independently hydrogen, alkyl or substituted alkyl or R.sup.4 and R.sup.5, together with the nitrogen to which they are attached, form a heterocycle, and B is alkylene or a group of formula --CH.sub.2 CH(OR.sup.6)CH.sub.2 --, where R.sup.6 is hydrogen, alkanoyl, substituted alkanoyl or arylcarbonyl, or a group of formula --D--R.sup.7, where D is a single bond or alkylene and R.sup.7 is a heterocycle; and A is alkylene; and pharmaceutically acceptable salts and esters thereof] are useful for the treatment and prevention of circulatory diseases and psychosis.
化合物的式子(I): ##STR1## [其中:R.sup.1是芳基;R.sup.2是氢、烷基、烷氧基、卤素或氰基;R.sup.3是式子--B--NR.sup.4 R.sup.5的基团,其中R.sup.4和R.sup.5独立地是氢、烷基或取代烷基或R.sup.4和R.sup.5与它们连接的氮一起形成杂环,而B是烷基或式子--CH.sub.2 CH(OR.sup.6)CH.sub.2 --的基团,其中R.sup.6是氢、烷酰基、取代烷酰基或芳基羰基,或式子--D--R.sup.7的基团,其中D是单键或烷基,并且R.sup.7是杂环;而A是烷基;以及其药学上可接受的盐和酯]对于治疗和预防循环系统疾病和精神病非常有用。